RPS6KB1 and lymphangioma: Activated mTOR may lead to the formation of LM by accelerating the growth and proliferation of cells and lymphangiogenesis by regulating the phosphorylation and activation of 4EBP and S6K, which provides a molecular principle for the development of mTOR-targeted therapy for LM (38, 39) (Figure 3).